The British company expects to report "substantial growth" in its food intolerance testing line for full-year 2009, and sales of its microarray-based Genarrayt platform are expected to rise 44 percent to £1.04 million from £72,000 in 2008.
So far this year, Rosetta has found commercialization partners for the diagnostics in the Middle East, Canada, the US, and India.
The arrangement gives Super Religare the rights to distribute the tests in India, Saudi Arabia, Qatar, and the United Arab Emirates.
SRL will distribute Rosetta’ Genomics’ microRNA cancer tests in India, Saudi Arabia, Qatar, and in the UAE.
The service is SRL's first array-based test and could foreshadow the adoption of more array-based diagnostics by the Indian testing giant.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.
The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.
ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.
In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.